EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, MorphoSys AG's Enterprise Value is €2,450.0 Mil.
MorphoSys AG's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was €-197.7 Mil. Therefore, MorphoSys AG's EV-to-FCF for today is -12.39.
The historical rank and industry rank for MorphoSys AG's EV-to-FCF or its related term are showing as below:
WBO:MOR'
s EV-to-FCF Range Over the Past 10 Years
Min: -592.87 Med: -19.41 Max: 279.66
Current: -12.39
During the past 13 years, the highest EV-to-FCF of MorphoSys AG was 279.66. The lowest was -592.87. And the median was -19.41.
WBO:MOR's EV-to-FCF is ranked worse than 100% of 393
companies
in the Biotechnology industry
Industry Median: 4.47
vs WBO:MOR: -12.39
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for MorphoSys AG's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of MorphoSys AG's EV-to-FCF
For the Biotechnology subindustry, MorphoSys AG's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MorphoSys AG's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MorphoSys AG's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where MorphoSys AG's EV-to-FCF falls into.
MorphoSys AG EV-to-FCF Calculation
MorphoSys AG's EV-to-FCF for today is calculated as:
MorphoSys AG's current Enterprise Value is €2,450.0 Mil.
MorphoSys AG's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-197.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MorphoSys AG (WBO:MOR) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
MorphoSys AG's PE Ratio for today is calculated as:
MorphoSys AG's share price for today is €66.15.
MorphoSys AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-5.520.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
MorphoSys AG EV-to-FCF Related Terms
Thank you for viewing the detailed overview of MorphoSys AG's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
WBO:MOR has been successfully added to your 